Author

Guang-Xian Xu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Autocrine PD-1-blocking nanobodies enhance the antitumor efficacy of TCR-like CAR-T cells by attenuating t cell exhaustion

Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in hematologic malignancies, but its efficacy against solid tumors is severely limited by two core barriers: the scarcity of uniformly expressed tumor-associated antigens (TAAs) and the immunosuppressive tumor microenvironment (TME), in wh...

Wan-Jun He, Kai Cui, Yi-Wei Zeng et al. · Journal of Translational Med... · 0 citations

Sep 2026

CircARHGAP10 inhibits colorectal cancer cell proliferation, migration and invasion by governing the miR-29a-5p/LPP axis and regulating Wnt/β-catenin signaling pathway.

It is revealed that circARHGAP10 functions as a tumor suppressor in CRC via two independent regulatory branches downstream of the circARHGAP10/miR-29a-5p cascade, and this newly identified circRNA-centered regulatory network provides a promising novel therapeutic target for CRC intervention.

Li-Yuan Liu, Yong-Cun Jia, Dong-Jie Li et al. · Molecular and Cellular Bioch... · 0 citations

Open access Jul 2026

Low-dose docetaxel reprograms CAR T cells for enhanced solid tumor immunity.

BACKGROUND Chimeric antigen receptor (CAR) T cell therapy in solid tumors is hampered by dense stromal barriers, rapid functional exhaustion, and limited persistence. Here, we report that low-dose docetaxel acts as an immunomodulatory primer that reprograms CAR T cells to address these barriers. Retrospective analysis...

Songshan Zhu, Jun Yin, Xin Fu et al. · Journal of experimental & cl... · 0 citations